• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 414640 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1418930256 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1418930256 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Watch for Continued Gains in Shares of Sanofi-Aventis (SNY)

Published on Wed, 01/02/2013 - 15:36
By Peter Chu

Sanofi-Aventis (NYSE:SNY) traded at a new 52-week high today of $48.10. This new high was reached on below average trading volume as 475,000 shares traded hands, while the average 30-day volume is approximately 1.2 million shares.

In the past 52 weeks, shares of Sanofi-Aventis have traded between a low of $33.03 and a high of $48.10 and are now at $47.75, which is 45% above that low price. Over the past week, the 200-day moving average (MA) has gone up 0.4% while the 50-day MA has advanced 0.6%.

Potential upside of 10.7% exists for Sanofi-Aventis, based on a current level of $47.75 and analysts' average consensus price target of $52.87. The stock should discover initial support at its 50-day moving average (MA) of $45.07 and subsequent support at its 200-day MA of $40.40.

Sanofi-Aventis is a global pharmaceutical company that researches, develops and manufactures prescription pharmaceuticals and vaccines. The Company develops cardiovascular, thrombosis, metabolic disorder, central nervous system, internal medicine and oncology drugs, and vaccines.

By Peter Chu
pchu@fnno.com

Latest News from FNNO

Buyers Accumulate Shares of Beazer Homes...

One of today's stocks on the move is Beazer Homes (NYSE:BZH), up 2.3% to $17.91. The D ...

Susquehanna Bancshares Trading Higher on...

The price of Susquehanna Bancshares shares has climbed to $13.19 (a 0.2% change) on hea ...

Stock Investors Bid Up Shares of Flamel ...

One of today's stocks on the move is Flamel Technologies (NASDAQ:FLML), up 2.3% to $17. ...

Sellers Reduce Exposure to Shares of Cor...

Shares of Corporate Office Properties Trust are trading today in above average volume, ...

Stock Investors Bid Up Shares of Fidelit...

Fidelity National Information Services (NYSE:FIS) is one of today's biggest movers, up ...

Multimedia Games Trading Higher on 1.8x ...

Shares of Multimedia Games are trading up 0.3% to $36.23 today on above average volume. ...

Movado Shares Sinking Lower, Down 2.3%...

One of today's stocks on the move is Movado (NYSE:MOV), down 2.3% to $27.26. The Dow i ...

Buyers Accumulating Shares of Cepheid on...

The price of Cepheid shares has climbed to $54.00 (a 8.5% change) on heavy trading volu ...